MYSTIC
Regimen
- Experimental
- durvalumab ± tremelimumab
- Control
- chemo
Population
1L metastatic NSCLC
Key finding
OS not significant (HR 0.76 not meeting threshold); bTMB signal; failed 1L IO-IO
Source: PMID 32271377
Timeline
- Enrollment start: 2015-07-21 📎
Guideline citations
- NCCN NSCLC Version 5.2026 (p.284)